News Source: The Day
| about 1 month ago
Pfizer Inc. has stopped enrolling patients in one late-stage clinical trial of a drug designed to treat lung cancer after testing resulted in an increase in adverse reactions, including fatalities. The drug, known as figitumumab, was first discovered...
News Source: Inquirer.net
| about 1 month ago
Pfizer Inc has halted patient enrollment in a late-stage lung cancer trial of its experimental drug, figitumumab, for safety reasons, the drugmaker said on Friday. The halt was recommended by independent safety monitors overseeing the study. In their...